Microba (ASX:MAP) posts 92% core testing growth as Nature Communications validates MAP-315

A 25,000-test run rate and a peer-reviewed readout reset the therapeutics optionality math.

Microba Life Sciences (ASX:MAP) has delivered a Q4 FY26 quarterly that does two things at once. It confirms the core testing engine is still compounding at pace, and it hands the therapeutics story a piece of independent validation that has been missing from the investment case.

Core testing revenue grew 92% for FY26 and volumes hit 22,418 tests, up 78% year-on-year. The exit annualised run rate now sits above 25,000 tests, and Q4 core testing revenue of A$2.53 million was up 45% on the prior corresponding period.

Sitting alongside those numbers is a genuinely notable development. The Phase 1 trial of MAP-315 in ulcerative colitis has been provisionally accepted for publication in Nature Communications. A tier-one journal picking up microbiome therapeutic data is not something the market has priced in.

The A$7 million per annum cost-out is substantially progressed, with the full benefit landing in H1 FY27. Cash at 30 June sat at A$7.95 million, before Tranche 2 of the recent placement settles later this month.

The Nature Communications acceptance changes the therapeutics conversation

Microbiome therapeutics has spent years fighting for scientific credibility. A provisional acceptance in Nature Communications for the MAP-315 Phase 1 data in ulcerative colitis is not a partnering deal, but it is the sort of external validation that partnering advisors can point at in a room full of pharma business development leads.

The timing is also worth noting. Between November 2025 and July 2026, six peer live biotherapeutic assets delivered positive clinical readouts, including Maat Pharma’s Phase 3 in GvHD and Microbiotica’s Phase 1b in IBD and oncology. The modality validation partners have been waiting on has largely arrived.

Microba is heading into a formal partnering campaign commencing this month, off the back of BIO International meetings in San Diego. We think the market is still valuing the therapeutics stack close to zero, and that may not survive a credible term sheet.

Enterprise clinics remain the growth engine with visible fuel

The 43 signed key accounts sold 5,606 tests in Q4, up 87% quarter-on-quarter. Management estimates those accounts alone represent ordering potential above 24,000 tests per year as they mature, roughly matching the current group run rate.

Behind that base sits a pipeline of over 175 key account targets with modelled ordering potential above 80,000 tests per annum. Even a modest conversion rate supports the FY27 growth thesis without needing heroic assumptions.

The UK is the sleeper leg. Ordering clinicians there grew 85% year-on-year to 313, and tests sold reached 825 in the quarter. The template is reproducing offshore, which matters for how the platform gets valued longer term.

GI Navigator launches into a wider prescriber base in September

GI Navigator remains on track for a September 2026 launch, with 35 early access sales already logged across Australian and UK opinion-leading clinicians. The product is designed to open the addressable market to more medical doctors rather than staying confined to the current integrative and functional medicine base.

That distinction matters. Broadening from allied health prescribers into a wider GP and specialist base changes both the addressable clinician count and the average revenue per test economics.

The risk sits in launch conversion. First 35 sales to friendly early adopters is a promising signal but not proof of a broad prescriber migration. The next two quarterlies will tell us whether GI Navigator is a product or a category.

The Investors Takeaway for Microba Life Sciences

The core testing business is now producing the sort of numbers a diagnostics investor can model with confidence. 92% growth, twelve consecutive quarters of expansion, and a category-defining product about to launch. That part of Microba is scaling on plan.

The more interesting question is whether the therapeutics stack starts to attract a valuation ahead of the diagnostics business hitting break-even. A Nature Communications publication, a validated modality across peer readouts, and an active partnering process with Boston advisors is not the same setup Microba had eighteen months ago. Investors can find our prior coverage at stocksdownunder.

GI Navigator conversion data and any therapeutics term sheet are the two catalysts investors should track. Either one, on its own, would meaningfully change how this small-cap gets modelled.